Oxford Biomedica's AAV platform, inAAVate™, provides advanced solutions for gene therapy. It focuses on high-quality, scalable manufacturing processes to ensure efficient and reliable production of adeno-associated virus vectors for clinical and commercial use.
Vendor
Oxford Biomedica
Company Website
Discover our unique inAAVate™ platform
Your AAV development partner, from construct design through GMP manufacturing
We offer end-to-end AAV development and manufacturing capabilities, from plasmid design and optimisation, to pre-clinical development, through clinical and commercial GMP manufacturing. These capabilities are supported by robust quality control systems, advanced analytical methods, and in-depth knowledge of global regulatory requirements.
Our Services
We provide a flexible service offering designed to support you wherever you are in your development journey – whether you are in early phase or ready for commercial GMP manufacturing.
- Construct & Plasmid Design
- Analytical Method Development
- Process Development
- GMP Cell Banking
- GMP Manufacturing
- QA Release
- Stability Studies
- Regulatory Support
Benefits
The inAAVate™ platform can provide:
- Faster time to GMP with a proven scalable approach
- Scalability from 2L up to 2,000L
- Improved drug product stability with patented formulation
- Higher titre and yield of drug substance with over 90% full vector which ensures a highly potent product
- Reduced use of raw materials, such as plasmids, needed for manufacturing with our Dual-Plasmid transfection system
- Proven formulation for over 10 AAV serotypes, eliminating the need for a tailor-made formulation
- Large suite of in-house analytical methods for an accelerated GMP batch release